Literature DB >> 25899469

Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy.

Dean Smith1, Clemency Stephenson2, Laura Percy3, Anna Lach2, Steve Chatters4, Helena Kempski4, Kwee Yong3.   

Abstract

Entities:  

Keywords:  FISH; myeloma therapy; prognostic factors

Mesh：

Substances：

Year:  2015        PMID： 25899469     DOI： 10.1111/bjh.13446

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Impact of acquired del(17p) in multiple myeloma.

Authors:  Arjun Lakshman; Utkarsh Painuly; S Vincent Rajkumar; Rhett P Ketterling; Prashant Kapoor; Patricia T Greipp; Angela Dispenzieri; Morie A Gertz; Francis K Buadi; Martha Q Lacy; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Adv       Date:  2019-07-09

2.  Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.

Authors:  Arash Latifoltojar; Margaret Hall-Craggs; Neil Rabin; Rakesh Popat; Alan Bainbridge; Nikolaos Dikaios; Magdalena Sokolska; Ali Rismani; Shirley D'Sa; Shonit Punwani; Kwee Yong
Journal:  Br J Haematol       Date:  2016-10-21       Impact factor: 6.998

3.  Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study.

Authors:  Timothy J P Bray; Saurabh Singh; Arash Latifoltojar; Kannan Rajesparan; Farzana Rahman; Priya Narayanan; Sahar Naaseri; Andre Lopes; Alan Bainbridge; Shonit Punwani; Margaret A Hall-Craggs
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

4.  Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.

Authors:  M Chin; J I Sive; C Allen; C Roddie; S J Chavda; D Smith; P Blombery; K Jones; G L Ryland; R Popat; A Rismani; S D'Sa; N Rabin; R E Gale; K L Yong
Journal:  Blood Cancer J       Date:  2017-09-15       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.